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low-up. Second, our study is the largest series of SIA under-
going selective stenting, but some variables had small num-
bers after partitioning. Therefore, any subanalysis performed
could underestimate the effect a variable imparts on patency.
Third, the incomplete and short-term follow-up limits the
applicability to long-term outcomes. Fourth, this study was
not designed to compare routine placement of stents vs place-
ment of selective or no stents. Our practice utilizes selective
placement of stents for a suboptimal result after SIA. While
there are defined criteria for suboptimal results, completion
angiogram interpretation after SIA remains quite subjective;
hence, leading to variable stent use by different surgeons.
Fifth, a wide variety and lengths of stents were utilized during
the study. The variability of performance between the differ-
ent types and lengths of stents may have confounded the
outcomes in the stent group. In addition, the difference in
stent lengths reflects both differences in the patient’s disease
processes and our bias to stenting only suboptimal segments.
Finally, there is a possibility of a type 2 error, especially in
subgroup analysis. This study, however, presents the largest
reported series on selective stenting after SIA; hence, the
possibility of a type 2 error is small.
Our study shows that selective stent placement can
salvage poor outcomes after SIA. This study neither affirms
nor refutes routine use of stents after SIA. A randomized
study comparing routine vs selective stent placement is
required to answer this important question.
CONCLUSIONS
Selective stents placed for suboptimal results after subintimal
angioplasty produces similar patency rates to primary SIA with-
out stenting. Patients with prior lower extremity bypass who
receive a stent after SIA will have worse patency than those
without prior bypass. Use of a stent diameter 6 mm and
indication of critical limb ischemia will likely produce worse
patency. Also, it appears that other specific stent variables (loca-
tion, number, length, and overlap) do not alter patency. Finally,
selective stent use after SIA provides excellent limb salvage.
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Gregory J. Pearl (Dallas, Tex). Dr. Schmieder and colleagues
report a large series of 368patients undergoing subintimal angioplasty
in superficial femoral and popliteal arteries. The purpose of the study
was to retrospectively review the selective use of stents and assess thelimbs, 84 (22%) received a stent and298 (78%) did not require a stent.
Stents were selectively placed for suboptimal results defined as greater
than 30% residual stenosis, dissection flaps or calcification.
One-year primary and secondary patency for the stent vs. no
stent groups was 50% vs. 45% and 70% vs. 78% respectively, the
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limb salvage rates between the stent and no stent group were also
comparable at 85% and 90% respectively, again with no statistical
difference. Maintenance of claudication relief and freedom from
bypass at one year were also comparable between the two groups.
Analysis of various factors revealed that the patency rates in
claudicants trended higher than for patients with limb threatening
ischemia at one year; that patients who had a previous ipsilateral
lower extremity bypass exhibited decreased one year patency com-
pared to those without a prior bypass; and that a stent diameter of
at least 7 mm displayed a trend toward better patency. Stent
length, overlap vs. non-overlap, and stent location did not appear
to be significant factors in the outcome.
I have two questions for the authors:
1) During the 3½ years time frame of the study, 639 limbs were
treated at your institution with subintimal angioplasty, a huge
number by anyone’s estimate. The mean follow-up time of the
patients in this study was just 10.9 months. The one-year
patency rates for this procedure is significantly inferior to
commonly accepted one-year patency rates for fem-pop bypass,
so my first question relates to the number of fem-pop bypasses
performed during this same time frame at your institution to
help us decipher your approach to the symptomatic patient
with long segment SFA occlusive disease. That is, what patients
in your practice will go to the endo suite and which will be
taken to the OR? For example, do you pursue an endovascular
approach first and reserve open bypass only for technical failures
or do you follow an algorithm based on patient comorbidities,
presence of suitable autogenous bypass conduit, runoff scores,
etc that you could share with us?
2) Second, I believe your study shows that stens may be used
successfully to salvage unacceptable angiographic results of SIA
to achieve comparable outcomes to SIA and PTA alone. You
acknowledge in the manuscript that this neither affirms nor
refutes the use of stents after SIA and that a prospective
randomized trial may be required. But based on inferior pa-
tency rates of SIA compared to known patency of fem-pop
bypass, especially over longer follow-up periods, don’t you
think prospective randomized trial comparing SIA and fem-
pop bypass might be more meaningful?I want to thank the authors for sending the manuscript for my
review in advance and congratulate them on a fine study.Gregory C. Schmieder. First, regarding the number of open
bypasses performed. We perform approximately 100-125 femoro-
popliteal and femorotibial bypasses per year.
Second, our approach to infrainguinal occlusive disease is to
be very aggressive with endovascular therapies. An endovascular
approach is pursued in selected patients who do not have a good
autogenous conduit, ie, previous CABG or bypass procedure,
and/or who are not good operative candidates. Patients with
critical ischemia have a high mortality at 3 years, approximately
40%. In addition, perioperative mortality and woundmorbidity for
open bypass has been cited as 2-5% and 10-15%, respectively. The
goal of therapy in this patient group is to preserve the limb. We feel
that we can provide excellent limb salvage for these patients at
lower morbidity and mortality. We have expanded this bias of
decreased morbidity and mortality out to patients with claudica-
tion. In addition, we are still preserving a vein for a bypass graft
down the road.
Third, as for looking at parameters on the angiogram to
pursue or not to pursue SIA, we are looking for distal targets. If
there is any distal target that we can re-enter into, we have an 88%
success rate with this intervention; so there is a subset of patients in
whom we cannot successfully perform a SIA. We are currently
trying to define angiographic parameters which can help us identify
patients with poor outcomes.
Fourth, our patency rates for SIA are inferior to standard open
autogenous bypass surgery. Should we not focus more on patient’s
clinical outcomes instead of patency rates? Is the patient’s relief of
claudication or limb salvagemore important to the patient than the
patency rate? Also, it takes longer for patients to recover from an
open bypass surgery than an endovascular procedure. SIA is a same
day procedure after which patients go home and resume activities
sooner than open bypass. When patients are seen in the office, both
endovascular and open options are discussed. We stress the advan-
tages and disadvantages of each approach; endovascular with less
morbidity, shorter hospital stay, quicker return to activity, but less
durability versus open surgery with more morbidity, longer hospi-
tal stay, slower return to activity, but longer durability. Another
putative advantage of endovascular therapy is the ability to re-
intervene and still keep an open surgical option available. The
overwhelming majority of patients chose the endovascular option.
Hence, a randomized, prospective study between open bypass and
SIA would be difficult to perform because most patients would not
consent to be randomized to a possible open intervention.
